Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Toronto, Canada, M5G-2C4
- Novo Nordisk Investigational Site
-
-
-
-
-
København ø, Denmark, 2100
- Novo Nordisk Investigational Site
-
-
-
-
-
Hamburg, Germany, 20246
- Novo Nordisk Investigational Site
-
Lahr, Germany, 77933
- Novo Nordisk Investigational Site
-
Mainz, Germany, 55131
- Novo Nordisk Investigational Site
-
-
-
-
-
Cambridge, United Kingdom, CB3 8RE
- Novo Nordisk Investigational Site
-
London, United Kingdom, W1G 8PH
- Novo Nordisk Investigational Site
-
Middlesborough, United Kingdom, TS4 3BW
- Novo Nordisk Investigational Site
-
Southampton, United Kingdom, SO16 6YD
- Novo Nordisk Investigational Site
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85714
- Novo Nordisk Investigational Site
-
-
California
-
San Francisco, California, United States, 94143
- Novo Nordisk Investigational Site
-
-
Colorado
-
Denver, Colorado, United States, 80262
- Novo Nordisk Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46290
- Novo Nordisk Investigational Site
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Novo Nordisk Investigational Site
-
-
New York
-
Bronx, New York, United States, 10467
- Novo Nordisk Investigational Site
-
Bronx, New York, United States, 10461
- Novo Nordisk Investigational Site
-
New York, New York, United States, 10032
- Novo Nordisk Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Novo Nordisk Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97207
- Novo Nordisk Investigational Site
-
Portland, Oregon, United States, 97239-3098
- Novo Nordisk Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Novo Nordisk Investigational Site
-
Philadelphia, Pennsylvania, United States, 19107-5092
- Novo Nordisk Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Novo Nordisk Investigational Site
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is undergoing his/her first myocardial revascularization
Exclusion Criteria:
- Previous participation (randomisation and dosing) in this trial
- Subject has a history of cerebrovascular event (including thrombotic or haemorrhagic stroke or transient ischaemic attack (TIA)) and/or extra-myocardial thromboembolic events, e.g., deep vein thrombosis (DVT) or pulmonary embolus (PE)
- Subject required a pre-operative (within 30 days) transfusion of any blood and/or blood product
- Subject has a current atrial fibrillation or history of atrial fibrillation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
|
|
Experimental: rFXIII
|
Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence and severity of adverse events
Time Frame: From dosing up to 5-7 weeks ± 3 days after trial product administration
|
From dosing up to 5-7 weeks ± 3 days after trial product administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence and magnitude of laboratory abnormalities following administration of rFXIII
Time Frame: From dosing up to 5-7 weeks ± 3 days after trial product administration
|
From dosing up to 5-7 weeks ± 3 days after trial product administration
|
|
Incidence of antibodies to FXIII-A subunit
Time Frame: From dosing up to 5-7 weeks ± 3 days after trial product administration
|
From dosing up to 5-7 weeks ± 3 days after trial product administration
|
|
Incidence of anti-yeast antibodies
Time Frame: From dosing up to 5-7 weeks ± 3 days after trial product administration
|
From dosing up to 5-7 weeks ± 3 days after trial product administration
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- F13CARD-1660
- 2005-000729-40 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.